Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease

Autor: Renske W. M. Pauwels, Christien J. van der Woude, Nicole S. Erler, Annemarie C. de Vries

Publikováno v: Therapeutic Advances in Gastroenterology, Vol 13 (2020)

Background and aims: Early prediction of the effect of vedolizumab (VDZ) in inflammatory bowel disease (IBD) is of paramount importance to guide clinical decisions. This study assessed whether early fecal calprotectin (FC) can predict endoscopic resp

Externí odkaz: https://doaj.org/article/924c781f712d443b84c2e2943d1c9b9c

Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) a pragmatic, open-label, non-inferiority, randomised controlled trial

Autor: Reinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, Lisa J T Smits, Femke Atsma, Wietske Kievit, Dirk J de Jong, Annemarie C de Vries, Paul J Boekema, Rachel L West, Alexander G L Bodelier, Ingrid A M Gisbertz, Frank H J Wolfhagen, Tessa E H Römkens, Maurice W M D Lutgens, Adriaan A van Bodegraven, Bas Oldenburg, Marieke J Pierik, Maurice G V M Russel, Nanne K de Boer, Rosalie C Mallant-Hent, Pieter C J ter Borg, Andrea E van der Meulen-de Jong, Jeroen M Jansen, Sita V Jansen, Adrianus C I T L Tan, C Janneke van der Woude, Frank Hoentjen, Desirée van Noord, Jildou Hoekstra, Johannes T. Kamphuis, Moniek H.P. Gorter, Aura A.J. van Esch

Publikováno v: Lancet Gastroenterology & Hepatology, 8, 4, pp. 343-355
Lancet Gastroenterology & Hepatology, 8, 343-355
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd
LADI study group and the Dutch Initiative on Crohn and Colitis 2023, ' Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) : a pragmatic, open-label, non-inferiority, randomised controlled trial ', The Lancet Gastroenterology and Hepatology, vol. 8, no. 4, pp. 343-355 . https://doi.org/10.1016/S2468-1253(22)00434-4
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd.

Item does not contain fulltext BACKGROUND: Despite its effectiveness in treating Crohn's disease, adalimumab is associated with an increased risk of infections and high health-care costs. We aimed to assess clinical outcomes of increased adalimumab d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4a13f67ca392c8811058105e50cf3a
https://repository.ubn.ru.nl/handle/2066/293716